By FieldPulse Editorial · March 8, 2026
Tags: hiring, oncology, pfizer
Pfizer is expanding its oncology field organization to support the growing Seagen ADC portfolio following the completion of commercial integration activities.
Pfizer has been adding oncology field representatives to support its expanded portfolio of antibody-drug conjugates (ADCs) inherited from its Seagen acquisition, as integration of the two commercial organizations continues. The ADC pipeline — spanning bladder, breast, lymphoma, and cervical cancer indications — has been a central element of Pfizer's oncology growth strategy following the $43 billion acquisition. Field coverage of the Seagen products has expanded significantly, with Padcev and Adcetris now part of a broader oncology call universe alongside Pfizer's legacy oncology portfolio. Fo